Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study

• Niklas Bergvall ,

  * E-mail: niklas.bergvall@novartis.com

  Affiliation Novartis Pharma AG, Basel, Switzerland

  ⨯
• Charles Makin,

  Affiliation IMS Health, Plymouth Meeting, Pennsylvania, United States of America

  ⨯
• Raquel Lahoz,

  Affiliation Novartis Pharma AG, Basel, Switzerland

  ⨯
• Neetu Agashivala,

  Affiliation Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America

  ⨯
• Ashish Pradhan,

  Affiliation Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, United States of America

  ⨯
• Gorana Capkun,

  Affiliation Novartis Pharma AG, Basel, Switzerland

  ⨯
• Allison A. Petrilla,

  Affiliation IMS Health, Plymouth Meeting, Pennsylvania, United States of America

  ⨯
• Swapna U. Karkare,

  Affiliation IMS Health, Plymouth Meeting, Pennsylvania, United States of America

  ⨯
• Catherine Balderston McGuiness,

  Affiliation IMS Health, Plymouth Meeting, Pennsylvania, United States of America

  ⨯
• Jonathan R. Korn

  Affiliation IMS Health, Plymouth Meeting, Pennsylvania, United States of America

  ⨯